

Tina Cascone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8621348/publications.pdf>

Version: 2024-02-01

55
papers

4,722
citations

257450

24
h-index

175258

52
g-index

57
all docs

57
docs citations

57
times ranked

8372
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037895.	6.2	24
2	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer, 2022, 164, 69-75.	2.0	2
3	Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1327-1337.	0.8	29
4	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
5	Current Surgical Indications for Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 1263.	3.7	23
6	Immunotherapy response-associated Akkermansia: canary in a coal mine?. Trends in Immunology, 2022, , .	6.8	3
7	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clinical Cancer Research, 2022, 28, 2461-2473.	7.0	9
8	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022, 13, 1970.	12.8	34
9	Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 189-203.	3.8	7
10	Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge December 1st-2nd, 2021. Journal of Translational Medicine, 2022, 20, .	4.4	3
11	Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC). Cancer Research, 2022, 82, CT124-CT124.	0.9	3
12	Pozotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell, 2022, 40, 754-767.e6.	16.8	34
13	Altered Regulation of HIF-1 α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. Journal of Thoracic Oncology, 2021, 16, 439-451.	1.1	34
14	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. Journal of Thoracic Oncology, 2021, 16, 127-139.	1.1	48
15	Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. European Journal of Cardio-thoracic Surgery, 2021, 59, 100-108.	1.4	23
16	Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 590-606.	2.8	25
17	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
18	Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers, 2021, 13, 1250.	3.7	7

#	ARTICLE	IF	CITATIONS
19	Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. <i>Lung Cancer</i> , 2021, 154, 76-83.	2.0	16
20	Evolution of systemic therapy for stages Iâ€“III non-metastatic non-small-cell lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 547-557.	27.6	152
21	Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?. <i>Lancet Oncology</i> , The, 2021, 22, 744-746.	10.7	3
22	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. <i>Cancer Discovery</i> , 2021, 11, 2506-2523.	9.4	68
23	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2051-2064.	1.1	6
24	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 5045.	12.8	42
25	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
26	Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1289-1297.	1.1	27
27	Inhibition of nonsense-mediated decay rescues p53 ^{Î²/Î³} isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. <i>Journal of Biological Chemistry</i> , 2021, 297, 101163.	3.4	18
28	What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2855-2858.	1.6	13
29	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1965-1976.	4.2	14
30	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 358-366.	1.3	9
31	Commentary: Neoadjuvant checkpoint inhibitors in resectable nonâ€“small cell lung cancerâ€“Ready for prime time?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1624-1625.	0.8	2
32	Emerging Therapies in Thoracic Malignanciesâ€“Immunotherapy, Targeted Therapy, and T-Cell Therapy in Nonâ€“Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 555-569.	1.5	6
33	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
34	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. <i>Lung Cancer</i> , 2020, 146, 303-309.	2.0	2
35	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	1.1	205
36	Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Nonâ€“Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. <i>Clinical Lung Cancer</i> , 2020, 21, e294-e301.	2.6	10

#	ARTICLE	IF	CITATIONS
37	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3525-3536.	7.0	22
38	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. <i>Clinical Lung Cancer</i> , 2020, 21, 341-348.	2.6	70
39	¹⁸ F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1519-1534.	4.2	21
40	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1449-1459.	1.1	109
41	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 603.	12.8	140
42	Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. <i>Oncologist</i> , 2019, 24, 772-782.	3.7	38
43	Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. <i>Journal of Clinical Oncology</i> , 2019, 37, 8504-8504.	1.6	101
44	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , 2018, 27, 977-987.e4.	16.2	398
45	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. <i>Modern Pathology</i> , 2018, 31, 947-955.	5.5	56
46	Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 105, 418-424.	1.3	26
47	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. <i>Journal of Thoracic Oncology</i> , 2018, 6, 48.		126
48	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. <i>Cancer Discovery</i> , 2018, 8, 1156-1175.	9.4	323
49	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5489-5501.	7.0	55
50	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	9.4	160
51	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
52	Can the Lung Cancer Pie Be Divided into Angiogenic Slices?. <i>Clinical Cancer Research</i> , 2015, 21, 5188-5190.	7.0	1
53	An integrin- $\alpha 3$ -KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. <i>Nature Cell Biology</i> , 2014, 16, 457-468.	10.3	325
54	Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy. <i>Cancer Research</i> , 2014, 74, 2731-2741.	0.9	41

#	ARTICLE	IF	CITATIONS
55	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2011, 121, 1313-1328.	8.2	141